Ahmedabad: Torrent Pharmaceuticals Limited announced on Tuesday that it will launch MSD (US-based Merck & Co., Known as MSD outside the US and Canada) and Ridgeback's Molnupiravir under the brand name Molnutor in India. Molnupiravir is an oral antiviral drug to treat mild to moderate Covid-19.
Earlier this year, Torrent Pharma entered into a non-exclusive voluntary license agreement with MSD for the manufacture, distribution and marketing of molnupiravir in more than 100 low- and middle-income markets, including India.
The Comptroller General of Medicines of India (DCGI), based on the review of clinical data of molnupiravir, approved the medicine for the treatment of Covid-19 in adults for emergency restricted use in India.
Molnupiravir is the oral antiviral approved by the UK Medicines and Health Products Regulatory Agency (MHRA) and the US Food and Drug Administration (USFDA) for emergency use authorization for the treatment of Covid- 19 mild to moderate in adults.
โWe are pleased to partner with MSD to bring Molnupiravir to patients across India. Molnupiravir will be an important addition to the ammunition of our healthcare system in the fight against Covid-19, โsaid Aman Mehta, CEO of Torrent Pharmaceuticals Limited.
Meanwhile, another major pharmaceutical company, Sun Pharma, also announced that one of its wholly owned subsidiaries has received emergency use authorization from DCGI to manufacture and market a generic version of Molnupiravir under the brand name Molxvir in India.
FacebookTwitterLinkedinE-mail
